News

RxPONDER Trial Results: Kevin Kalinsky, MD
Dec 1, 2021
RxPONDER finds postmenopausal women with HR+, HER2- breast cancer with 1-3 involved nodes and an RS of 25 or less can safely skip chemo
SWOG Front Line Banner
Sep 24, 2021
Adults with cancer in the U.S. gained 14 million years of life from 40 years of NCTN trials.
ESMO Congress 2021
Sep 20, 2021
Forty years of publicly funded trials added 14 million years of life for cancer patients and profoundly affected cancer care guidelines
Clinical Cancer Research article
Sep 14, 2021
A blood serum test can identify which patients have slow-growing disease that might be controlled with an aromatase inhibitor alone.